{"id":3374,"date":"2016-12-08T10:38:06","date_gmt":"2016-12-08T01:38:06","guid":{"rendered":"http:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/contents\/?p=3374"},"modified":"2016-12-08T10:38:06","modified_gmt":"2016-12-08T01:38:06","slug":"2015%e5%b9%b4%e6%a5%ad%e7%b8%be%e3%80%80%e3%81%9d%e3%81%ae2","status":"publish","type":"post","link":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/%e7%a0%94%e7%a9%b6%e7%b4%b9%e4%bb%8b\/3374\/","title":{"rendered":"2015\u5e74\u696d\u7e3e\u3000\u305d\u306e2"},"content":{"rendered":"

2015\u5e74\u696d\u7e3e\u3000\u305d\u306e2
\n\u25a0\u3000\u5b66\u4f1a\u30fb\u7814\u7a76\u4f1a\u767a\u8868
\n\u56fd\u5185\u5b66\u4f1a\uff08\u5168\u56fd\uff09<\/a>
\n\u56fd\u5185\u5b66\u4f1a\uff08\u5730\u65b9\u4f1a\uff09<\/a>
\n\u25a0 \u8b1b\u6f14<\/a>
\n\u25a0 \u7814\u7a76\u52a9\u6210<\/a>
\n\u25a0 \u53d7\u8cde<\/a>
\n\u8ad6\u6587\u3001\u56fd\u969b\u5b66\u4f1a\u767a\u8868\u306f2015\u5e74\u696d\u7e3e\u3000\u305d\u306e1<\/a>\u3092\u3054\u89a7\u4e0b\u3055\u3044\u3002
\n—————————
\n\u25a0<\/span> \u5b66\u4f1a\u767a\u8868(\u56fd\u5185)<\/strong>
\n<\/a>\u25cf<\/span> \u56fd\u5185\u5b66\u4f1a(\u5168\u56fd)<\/p>\n

    \n1.\u57ce\u6238\u502b\u4e4b, \u6e21\u8fba\u5f18\u6bc5, \u57ce\u6238\u8f1d\u4ec1, \u671b\u6708\u8f1d\u4e00. Single-breath-hold Real-Time cine MR\u3092\u7528\u3044\u305f\u5de6\u5ba4\u5bb9\u91cf\u8a55\u4fa1\u306e\u6709\u7528\u6027. \u7b2c25\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u753b\u50cf\u52d5\u614b\u5b66\u4f1a\uff082015.1, \u6771\u4eac\uff09
    \n2.\u7530\u908a\u88d5\u8cb4, \u57ce\u6238\u8f1d\u4ec1, \u798f\u5c71\u76f4\u7d00, \u677e\u7530\u5353\u4e5f, \u5009\u7530 \u8056, \u6cb3\u91ce\u73e0\u7f8e, \u4e0a\u8c37\u6643\u7531, \u5927\u6728\u5143\u660e\u7fa9, \u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. \u51a0\u52d5\u8108\u75be\u60a3\u306e\u8a3a\u65ad\u306b\u304a\u3051\u308bCoronary CTA\uff0bDynamic CT perfusion\u4f75\u7528\u30d7\u30ed\u30c8\u30b3\u30fc\u30eb\u306e\u6709\u7528\u6027\u306b\u3064\u3044\u3066. \u7b2c25\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u753b\u50cf\u52d5\u614b\u5b66\u4f1a\uff082015.1, \u6771\u4eac\uff09
    \n3.\u5ddd\u53e3\u76f4\u4eba, \u83ca\u6c60\u9686\u5fb3, \u4e95\u4e0a\u6b66, \u4e09\u6728\u5747, \u4ed6. N-13\u30a2\u30f3\u30e2\u30cb\u30a2PET\u306b\u304a\u3051\u308b\u51a0\u8840\u6d41\u4e88\u5099\u80fd\u8a55\u4fa1\u306e\u521d\u671f\u7d4c\u9a13. \u7b2c25\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u753b\u50cf\u52d5\u614b\u5b66\u4f1a\uff082015.1, \u6771\u4eac\uff09
    \n4.\u798f\u5c71\u76f4\u7d00, \u57ce\u6238\u8f1d\u4ec1, \u7530\u908a\u88d5\u8cb4, \u6a2a\u5c71\u3089\u307f, \u4e2d\u6751\u58ee\u5fd7, \u677e\u7530\u5353\u4e5f, \u897f\u5c71\u9999\u5b50, \u5009\u7530 \u8056, \u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. \u5fc3\u81d3CT\u3092\u7528\u3044\u305f\u51a0\u52d5\u8108\u652f\u914d\u704c\u6d41\u57df\u89e3\u6790\u30bd\u30d5\u30c8\u30a6\u30a7\u30a2\u306e\u6574\u5408\u6027\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e\uff1aATP\u8ca0\u8377\u5fc3\u81d3MRI\u3068\u306e\u6bd4\u8f03. \u7b2c80\u56de\u5fc3\u81d3\u653e\u5c04\u7dda\u7814\u7a76\u4f1a\uff082015.1, \u6771\u4eac\uff09
    \n5.\u6e05\u6c34\u8f1d\u5f66, \u897f\u5cf6\u7d00\u5b50, \u7d30\u5ddd\u6d69\u5e73, \u68b6\u539f \u8aa0, \u9ad8\u6a4b\u5fe0\u7ae0, \u9152\u4e95\u4f38\u4e5f, \u83c5\u539f\u656c\u6587, \u6e05\u85e4\u4f50\u77e5\u5b50, \u9ad8\u6a4b\u4e09\u5948, \u9ad8\u5d8b\u6210\u8f1d, \u9752\u5100\u5065\u4e8c\u90ce, \u5927\u4f4f\u7701\u4e09, \u897f\u6751\u7406\u6075\u5b50. \u4e73\u817alarge cell neuroendocrine carcinoma\u306e1\u4f8b. \u7b2c24\u56de\u65e5\u672c\u4e73\u764c\u753b\u50cf\u7814\u7a76\u4f1a\uff082015. 2, \u6771\u4eac\uff09
    \n6.\u83ca\u6c60\u9686\u5fb3, \u4e95\u4e0a \u6b66, \u4e09\u6728 \u5747, \u677e\u672c\u96c4\u53f8, \u5965\u7530\u6587\u543e. \u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u8133\u7b4b\u75c7\u306e\u4e00\u4f8b. \u7b2c122\u56de\u6838\u533b\u5b66\u75c7\u4f8b\u691c\u8a0e\u4f1a\uff082015.2, \u5c3c\u5d0e\uff09
    \n7.\u5e73\u585a\u7fa9\u5eb7, \u83ca\u6c60\u6075\u4e00, \u671b\u6708\u8f1d\u4e00, \u9ad8\u91ce\u660c\u5e73, \u5927\u4e0a\u53f2\u6717, \u4e95\u4e0a \u6b66, \u4e09\u6728 \u5747. \u8133\u816b\u760d\u306b\u304a\u3051\u308b11C-Methionine\u30fb18F-FDG PET\/CT\u96c6\u7a4d\u306e\u691c\u8a0e. \u7b2c44\u56de\u65e5\u672c\u795e\u7d4c\u653e\u5c04\u7dda\u5b66\u4f1a\uff082015.3, \u540d\u53e4\u5c4b\uff09
    \n8.\u4e09\u6728\u3000\u5747, \u68ee \u5343\u5c0b, \u5c0f\u5ddd \u907c, \u77f3\u4e38\u826f\u5e83, \u83ca\u6c60\u9686\u5fb3, \u4e95\u4e0a \u6b66. \u4e2d\u5927\u8133\u8108\u9818\u57df\u306e\u6025\u6027\u671f\u8133\u6897\u585e\u306b\u304a\u3051\u308b3D ASL\uff1aMRA\u3001FLAIR\u3068\u306e\u6bd4\u8f03. \u7b2c44\u56de\u65e5\u672c\u795e\u7d4c\u653e\u5c04\u7dda\u5b66\u4f1a\uff082015.3, \u540d\u53e4\u5c4b\uff09
    \n9.\u6ff1\u672c \u6cf0, \u897f\u5d0e \u7d71, \u7a32\u7530\u5b8f\u898f, \u6817\u6797\u4f51\u591a. \u8133\u5b9a\u4f4d\u7167\u5c04\u3092\u7e70\u308a\u8fd4\u3057\u65bd\u884c\u3057\u305f\u75c7\u4f8b\u306e\u691c\u8a0e. \u30b5\u30a4\u30d0\u30fc\u30ca\u30a4\u30d5\u7814\u7a76\u4f1a\u3000\u7b2c9\u56de\u5b66\u8853\u7814\u7a76\u4f1a\uff082015.3, \u6771\u4eac\uff09
    \n10.Kurata A, Kono A, Nieman K, Nishiyama Y, Kido T, Abe M, Higashino H, Uetani T, Ogimoto A, Higaki J, Miyagawa M, Mochizuki T. Automated Quantification of Myocardial Area at Risk Using Coronary CT Angiography and Voronoi Algorithm Based Myocardial Segmentation on CT. Plenary Session 1. The 79th Annual Scientific Meeting of the Japanese Circulation Society. (2015.4, \u5927\u962a)
    \n11.\u7d30\u5ddd\u6d69\u5e73, \u83c5\u539f\u656c\u6587, \u897f\u5cf6\u7d00\u5b50, \u68b6\u539f \u8aa0, \u6e05\u6c34\u8f1d\u5f66, \u9ad8\u6a4b\u5fe0\u7ae0, \u9152\u4e95\u4f38\u4e5f, \u9ad8\u7551\u6d69\u4e4b, \u5927\u7530\u8015\u53f8, \u68da\u7530 \u7a14. \u5927\u8178\u764c\u809d\u8ee2\u79fb\u306b\u304a\u3051\u308b\u62e1\u6563\u5f37\u8abfMRI\u306eADC\u3068FDG-PET\/CT\u306eSUV\u3068\u306e\u6bd4\u8f03. \u7b2c74\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a (2015.4, \u6a2a\u6d5c)
    \n12.Kido T, Watanabe K, Nakamura M, Mochizuki T. Free-Breath Real-Time Cardiac Cine MR for Evaluation of Left Ventricular Function. \u7b2c74\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff082015.4, \u6a2a\u6d5c\uff09
    \n13.Nishikawa A, Uwatsu K, Kanzaki H, Nagasaki K, Nishijima N, Kataoka M. Stereotactic body radiotherapy for primary and metastatic lung cancer. \u7b2c74\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a (2015.4, \u6a2a\u6d5c)
    \n14.Yokoyama R, Miyagawa M, Tanabe Y, Matsuda T, Nakamura M, Nishiyama Y, Kawaguchi N, Kido TO, Kido TE, Ogimoto A, Higaki J, Mochizuki T. Detection of Cardiac Involvement in Sarcoidosis: Assessment by Image Fusion with Delayed-Enhanced MRI and F-18 FDG PET\/CT. \u7b2c74\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a (2015.4, \u6a2a\u6d5c)
    \n15.\u6ff1\u672c \u6cf0, \u7a32\u7530\u5b8f\u898f, \u6817\u6797\u4f51\u591a, \u974d\u5ca1\u614e\u592a\u90ce, \u6b66\u7530\u82f1\u6a39, \u771f\u934b\u4fca\u6cbb, \u897f\u5d0e \u7d71. Experiences of repeat stereotactic radiosurgery\/radiotherapy for metastatic brain tumors. \u7b2c74\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a (2015.4, \u6a2a\u6d5c)
    \n16.Tsuda T, Koiwahara G, Hirata M, Tanaka H, Mochizuki T. Staging of advanced colorectal cancer by contrast-enhanced CT colonography. \u7b2c74\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a (2015.4, \u6a2a\u6d5c)
    \n17.Ide K, Miyagawa M, Yokoyama R, Nishiyama Y, Mochizuki T. Clinical characteristics of pulmonary pleomorphic carcinoma on FDG PET\/CT. \u7b2c74\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff082015.4, \u6a2a\u6d5c\uff09
    \n18.Yokoyama R, Miyagawa M, Okayama H, Inoue T, Miki H, Ogimoto A, Higaki J, Mochizuki T. PET\/CT Quantification of Myocardial F-18 FDG Uptake for Detection of Cardiac Sarcoidosis using a ROC Analysis. \u7b2c74\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff082015.4, \u6a2a\u6d5c\uff09
    \n19.Taguchi S, Nakajima N, Ochi T, Mochizuki T. The outcome of postoperative radiation therapy with or without chemotherapy for primary and recurrent oral cavity squamous cell carcinoma. \u7b2c74\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff082015.4, \u6a2a\u6d5c\uff09
    \n20.Fukuyama N, Kido T, Tanabe Y, Yokoyama R, Nakamura M, Matsuda T, Nishiyama Y, Kurata A, Miyagawa M, Mochizuki T. Assessment of software for automated analysis of myocardial area at risk based on CCTA data: Comparison with stress perfusion CMR. \u7b2c74\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff082015.4, \u6a2a\u6d5c\uff09
    \n21.\u5c0f\u5ddd \u907c, \u5ddd\u53e3\u76f4\u4eba, \u83ca\u6c60\u9686\u5fb3, \u4e09\u6728 \u5747, \u57ce\u6238\u8f1d\u4ec1, \u671b\u6708\u8f1d\u4e00. The detection of in-stent restenosis and the risk factor by dual source CT coronary angiography. \u7b2c74\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff082015.4, \u6a2a\u6d5c\uff09
    \n22.Tanabe Y, Kido T, Matsuda T, Kawaguchi N, Yokoyama R, Nakamura M, Nishiyama Y, Miyagawa M, Mochizuki T. Diagnostic Accuracy of Enhancement Ratio of Myocardium to Aorta derived from dynamic computed tomography perfusion image. \u7b2c74\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff082015.4, \u6a2a\u6d5c\uff09
    \n23.Kawaguchi N, Kikuchi T, Inoue T, Miki H. Combined the detection of significant coronary artery stenosis using hybrid imaging of cardiac CT and 13N-ammmonia PET. \u7b2c74\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff082015.4, \u6a2a\u6d5c\uff09
    \n24.\u68ee\u3000\u5343\u5c0b, \u4e09\u6728 \u5747, \u5c0f\u5ddd \u907c, \u677e\u7530 \u6075, \u6751\u4e0a\u5fe0\u53f8, \u77f3\u4e38\u826f\u5e83, \u83ca\u6c60\u9686\u5fb3, \u4e95\u4e0a\u3000\u6b66, \u5ca1\u672c\u61b2\u7ae0, \u6cb3\u91ce\u517c\u4e45. Arterial spin labeling (ASL) in acute cerebral infarction. \u7b2c74\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff082015.4, \u6a2a\u6d5c\uff09
    \n25.\u5bae\u5185\u7b11\u9e97, \u4e95\u4e0a \u6b66, \u4e09\u6728 \u5747, \u540d\u548c\u7531\u4e00\u90ce, \u6728\u85e4\u514b\u5df3. \u8840\u7ba1\u5185\u30ea\u30f3\u30d1\u816b\u306eFDG\u3000PET\u6240\u898b. \u7b2c74\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff082015.4, \u6a2a\u6d5c\uff09
    \n26.\u5ddd\u53e3\u76f4\u4eba, \u83ca\u6c60\u9686\u5fb3, \u4e95\u4e0a \u6b66, \u4e09\u6728 \u5747, \u4ed6. \u5fc3\u81d3CT\u30fb\u30a2\u30f3\u30e2\u30cb\u30a2PET\u878d\u5408\u753b\u50cf\u304c\u591a\u679d\u75c5\u5909\u306b\u304a\u3051\u308b\u5fc3\u7b4b\u865a\u8840\u306e\u5224\u5b9a\u306b\u6709\u7528\u3067\u3042\u3063\u305f1\u4f8b. Beyond Angiography Japan XX\uff082015.4, \u5927\u962a\uff09
    \n27.\u5bae\u5185\u7b11\u9e97, \u4e09\u6728 \u5747. \u7279\u6b8a\u306a\u5f62\u614b\u3092\u793a\u3057\u305fDiffuse astrocytoma\u306e1\u4f8b. \u7b2c\uff17\u56de\u810a\u690e\u30fb\u810a\u9ac4\u753b\u50cf\u30af\u30e9\u30d6\uff082015.4, \u6771\u4eac\uff09
    \n28.\u974d\u5ca1\u614e\u592a\u90ce, \u6ff1\u672c \u6cf0, \u6b66\u7530\u82f1\u6a39, \u771f\u934b\u4fca\u6cbb, \u4ed6. 3\u56de\u4ee5\u4e0a\u306e\u8133\u5b9a\u4f4d\u7167\u5c04\u3092\u7e70\u308a\u8fd4\u3057\u65bd\u884c\u3057\u305f\u75c7\u4f8b\u306e\u691c\u8a0e. \u65e5\u672c\u653e\u5c04\u7dda\u816b\u760d\u5b66\u4f1a\u7b2c28\u56de\u9ad8\u7cbe\u5ea6\u653e\u5c04\u7dda\u5916\u90e8\u7167\u5c04\u7814\u7a76\u4f1a\uff082015.5, \u4eac\u90fd\uff09
    \n\u6ff1\u672c \u6cf0, \u7a32\u7530\u5b8f\u898f, \u6817\u6797\u4f51\u591a, \u974d\u5ca1\u614e\u592a\u90ce, \u6b66\u7530\u82f1\u6a39, \u771f\u934b\u4fca\u6cbb. \u30b5\u30a4\u30d0\u30fc\u30ca\u30a4\u30d5\u306b\u3088\u308b\u8ee2\u79fb\u6027\u810a\u690e\u816b\u760d\u306e\u6cbb\u7642\u7d4c\u9a13. \u65e5\u672c\u653e\u5c04\u7dda\u816b\u760d\u5b66\u4f1a\u7b2c28\u56de\u65e5\u672c\u9ad8\u7cbe\u5ea6\u653e\u5c04\u7dda\u5916\u90e8\u7167\u5c04\u7814\u7a76\u4f1a\uff082015.5, \u4eac\u90fd\uff09
    \n29.Kawaguchi N, Ishimaru Y, Murakami T, Miki H, Hirata M, Tanaka H. Transcatheter arterial embolization of spontaneous retroperitoneal hemorrhage. \u7b2c44\u56de\u65e5\u672cIVR\u5b66\u4f1a\u7dcf\u4f1a\uff082015.5, \u5bae\u5d0e\uff09
    \n30.\u5bae\u5ddd\u6b63\u7537. \u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u300c\u5fc3\u7b4b\u8840\u6d41\u306e\u5b9a\u91cf\u89e3\u6790\u300d Discovery NM530c\u3092\u7528\u3044\u305f\u5fc3\u7b4b\u8840\u6d41\u306e\u5b9a\u91cf. \u7b2c25\u56de\u65e5\u672c\u5fc3\u81d3\u6838\u533b\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a\uff082015.6, \u6771\u4eac\uff09
    \n31.\u897f\u5c71\u9999\u5b50, \u5bae\u5ddd\u6b63\u7537, \u6a2a\u5c71\u3089\u307f, \u6a2a\u4e95\u656c\u5f18, \u5c0f\u5ddd \u907c, \u798f\u5c71\u76f4\u7d00, \u7530\u908a\u88d5\u8cb4, \u57ce\u6238\u502b\u4e4b, \u57ce\u6238\u8f1d\u4ec1, \u671b\u6708\u8f1d\u4e00. \u534a\u5c0e\u4f53SPECT\u88c5\u7f6e\u3092\u7528\u3044\u305f\u88ab\u66dd\u4f4e\u6e1b\u30d7\u30ed\u30c8\u30b3\u30fc\u30eb\u306b\u95a2\u3059\u308b\u691c\u8a0e. \u7b2c25\u56de\u65e5\u672c\u5fc3\u81d3\u6838\u533b\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a\uff082015.6, \u6771\u4eac\uff09
    \n32.\u7530\u4ee3\u3089\u307f, \u5bae\u5ddd\u6b63\u7537, \u5ca1\u5c71\u82f1\u6a39, \u4e95\u4e0a\u6b66, \u4e09\u6728\u5747, \u5927\u6728\u5143\u660e\u7fa9, \u6a9c\u57a3\u5be6\u7537, \u671b\u6708\u8f1d\u4e00. F-18 FDG PET\/CT\u306b\u304a\u3051\u308b\u5fc3\u30b5\u30eb\u30b3\u30a4\u30c9\u30fc\u30b7\u30b9\u306e\u5fc3\u96c6\u7a4d: ROC\u89e3\u6790\u3092\u7528\u3044\u305f\u5b9a\u91cf\u8a55\u4fa1. \u7b2c25\u56de\u65e5\u672c\u5fc3\u81d3\u6838\u533b\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a (2015.6, \u6771\u4eac)
    \n33.\u6d25\u7530\u5b5d\u6cbb, \u5c0f\u5ca9\u539f\u5143, \u5e73\u7530\u96c5\u662d, \u7530\u4e2d\u5b8f\u660e, \u671b\u6708\u8f1d\u4e00, \u5150\u5cf6\u3000\u6d0b, \u6e21\u90e8\u7950\u53f8. \u9577\u671f\u7d4c\u904e\u3092\u8ffd\u3048\u305f\u8178\u9593\u819c\u306ePlasma cell Castleman\u75c5\u306e\u4e00\u4f8b. \u7b2c29\u56de\u65e5\u672c\u8179\u90e8\u653e\u5c04\u7dda\u5b66\u4f1a (2015.6, \u6d5c\u677e)
    \n34.Matsuda M, Miki H, Mori C, Murakami T, Inoue T. A case of liver amyloidosis. \u7b2c29\u56de\u65e5\u672c\u8179\u90e8\u653e\u5c04\u7dda\u5b66\u4f1a\uff082015.6, \u6d5c\u677e\uff09
    \n35.\u897f\u5cf6\u7d00\u5b50, \u83c5\u539f\u656c\u6587, \u7d30\u5ddd\u6d69\u5e73, \u68b6\u539f \u8aa0, \u6e05\u6c34\u8f1d\u5f66, \u9ad8\u6a4b\u5fe0\u7ae0, \u9152\u4e95\u4f38\u4e5f, \u5927\u7530\u8015\u53f8, \u68da\u7530 \u7a14, \u9ad8\u7551\u6d69\u4e4b, \u5bfa\u672c\u5178\u5f18. \u81b5PEComa\u306e1\u4f8b. \u7b2c29\u56de\u65e5\u672c\u8179\u90e8\u653e\u5c04\u7dda\u5b66\u4f1a (2015.6, \u6d5c\u677e)
    \n36.\u897f\u5cf6\u7d00\u5b50, \u83c5\u539f\u656c\u6587, \u7d30\u5ddd\u6d69\u5e73, \u68b6\u539f \u8aa0, \u6e05\u6c34\u8f1d\u5f66, \u9ad8\u6a4b\u5fe0\u7ae0, \u9152\u4e95\u4f38\u4e5f, \u843d\u5408\u4eae\u4e8c, \u5c0f\u6797\u6210\u884c, \u5c0f\u7560\u8a89\u4e5f, \u9ad8\u7551\u6d69\u4e4b. \u5de8\u5927\u306a\u816b\u7624\u3092\u5f62\u6210\u3057\u305f\u8179\u819c\u60aa\u6027\u4e2d\u76ae\u816b\u306e1\u4f8b. \u7b2c29\u56de\u65e5\u672c\u8179\u90e8\u653e\u5c04\u7dda\u5b66\u4f1a (2015.6, \u6d5c\u677e)
    \n37.\u5bae\u5185\u7b11\u9e97, \u4e09\u6728 \u5747. \u816b\u760d\u8fba\u7e01\u306bhemosiderin rim\u3092\u8a8d\u3081\u305f\u9ac4\u819c\u816b\u306e1\u4f8b. \u7b2c35\u56de\u795e\u7d4c\u653e\u5c04\u7dda\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7\uff082015.6, \u798f\u5ca1\uff09
    \n38.\u6a2a\u4e95\u656c\u5f18, \u7530\u908a\u88d5\u8cb4, \u57ce\u6238\u8f1d\u4ec1, \u798f\u5c71\u76f4\u7d00, \u6a2a\u5c71\u3089\u307f, \u897f\u5c71\u9999\u5b50, \u57ce\u6238\u502b\u4e4b, \u5009\u7530\u8056, \u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. \u5fc3\u81d3CT\u306b\u3088\u308b\u5de6\u5ba4\u5fc3\u7b4b3D maximum principal strain\u306e\u6b63\u5e38\u7bc4\u56f2\/\u50be\u5411\u306b\u95a2\u3059\u308b\u691c\u8a0e. \u7b2c81\u56de\u65e5\u672c\u5fc3\u81d3\u8840\u7ba1\u653e\u5c04\u7dda\u7814\u7a76\u4f1a\uff082015.7, \u672d\u5e4c\uff09
    \n39.\u5c0f\u5ddd \u907c, \u57ce\u6238\u502b\u4e4b, \u6a2a\u4e95\u656c\u5f18, \u798f\u5c71\u76f4\u7d00, \u7530\u908a\u88d5\u8cb4, \u7530\u4ee3\u3089\u307f, \u897f\u5c71\u9999\u5b50, \u57ce\u6238\u8f1d\u4ec1, \u5009\u7530 \u8056, \u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. 3T MR\u3092\u7528\u3044\u305fsaturation recovery\u6cd5\u306b\u3088\u308bT1mapping; \u6b63\u5e38\u7fa4\u3068\u80a5\u5927\u578b\u5fc3\u7b4b\u75c7\u306e\u9451\u5225. \u7b2c81\u56de\u65e5\u672c\u5fc3\u81d3\u8840\u7ba1\u653e\u5c04\u7dda\u7814\u7a76\u4f1a\uff082015.7, \u672d\u5e4c\uff09
    \n40.Tanabe Y, Kido TE, Yokoi T, Fukuyama N, Sawada S, Suekuni H, Ogawa R, Nishiyama Y, Kido TO, Kurata A, Miyagawa M, Mochizuki T. Quantitative Assessment of Left Ventricular Three-Dimensional Maximum Principal Strain using Cardiac Computed Tomography: Identification of Myocardial Infarction Assessed by Cardiac Magnetic Resonance Imaging. \u7b2c81\u56de\u65e5\u672c\u5fc3\u81d3\u8840\u7ba1\u653e\u5c04\u7dda\u7814\u7a76\u4f1a\uff082015.7, \u672d\u5e4c\uff09
    \n41.\u4ec1\u4e95\u7530\u308a\u3061, \u4ec1\u4e95\u7530\u660e, \u677e\u7530\u535a\u53f2. \u5927\u3046\u3064\u75c5\uff08MDD\uff09\u3068\u53cc\u6975\u6027\u969c\u5bb3\uff08BD\uff09\u306e\u8a3a\u65ad\u306b\u304a\u3044\u3066\u8133\u5c40\u6240\u306e\u5909\u5316\u304c\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc\u3068\u306a\u308a\u3046\u308b. \u7b2c\uff11\uff12\u56de\u65e5\u672c\u3046\u3064\u75c5\u5b66\u4f1a\u7dcf\u4f1a\uff082015.8, \u6771\u4eac\uff09
    \n42.\u4ec1\u4e95\u7530\u660e, \u4ec1\u4e95\u7530\u308a\u3061, \u677e\u7530\u535a\u53f2. VSRAD\u3092\u5fdc\u7528\u3057\u305f\u5927\u3046\u3064\u75c5\u88dc\u52a9\u8a3a\u65ad\u306b\u304a\u3051\u308b\u9752\u58ee\u5e74\u8005\u30c7\u30fc\u30bf\u30d9\u30fc\u30b9\u4f5c\u6210\u306e\u8a66\u307f. \u7b2c\uff11\uff12\u56de\u65e5\u672c\u3046\u3064\u75c5\u5b66\u4f1a\u7dcf\u4f1a\uff082015.8, \u6771\u4eac\uff09
    \n43.\u4ec1\u4e95\u7530\u308a\u3061\u3001\u4ec1\u4e95\u7530\u660e, \u677e\u7530\u535a\u53f2. \u96e3\u6cbb\u6027\u3046\u3064\u75c5\u3068\u8a3a\u65ad\u3055\u308c\u308b\u60a3\u8005\u7fa4\u306e\u691c\u8a0e-\u6881\u4e0b\u91ce(SCA:BA2\u91ce)\u840e\u7e2e\u3068\u7279\u5fb4\u7684\u306a\u85ac\u7269\u53cd\u5fdc\u6027\u306e\u95a2\u9023\u306b\u3064\u3044\u3066. \u7b2c\uff11\uff12\u56de\u65e5\u672c\u3046\u3064\u75c5\u5b66\u4f1a\u7dcf\u4f1a\uff082015.8, \u6771\u4eac\uff09
    \n44.\u5c71\u672c\u5c1a\u5e78. \u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u4eca\u5f8c\u306e\u653e\u5c04\u7dda\u4e8b\u6545\uff65\u707d\u5bb3\u5bfe\u5fdc\uff0d\u591a\u6a5f\u95a2\u9023\u643a\u306e\u3042\u308a\u65b9\uff0d\u3000\u6559\u80b2\u306b\u95a2\u3057\u3066. \u7b2c3\u56de\u65e5\u672c\u653e\u5c04\u7dda\u4e8b\u6545\u30fb\u707d\u5bb3\u533b\u5b66\u4f1a\uff082015.8\uff0c\u798f\u5cf6\uff09
    \n45.\u897f\u5cf6\u7d00\u5b50, \u53ea\u4fe1\u7f8e\u7d00, \u7d30\u5ddd\u6d69\u5e73, \u68b6\u539f \u8aa0, \u6e05\u6c34\u8f1d\u5f66, \u9ad8\u6a4b\u5fe0\u7ae0, \u9152\u4e95\u4f38\u4e5f, \u83c5\u539f\u656c\u6587, \u4ed6. Seromucinous borderline tumor\u306e3\u4f8b. JSAWI2015, 16th Annual Symposium (2015.9, \u6de1\u8def)
    \n46.\u5c0f\u677e\u6b63\u660e, \u6960\u672c\u771f\u4e5f, \u5927\u4e80\u771f\u4e00, \u767d\u5c71\u88d5\u5b50, \u6a2a\u5c71 \u9686, \u83c5\u539f\u656c\u6587, \u7af9\u539f\u548c\u5b8f. \u5375\u5de3\u4f4e\u60aa\u6027\u5ea6\u6f3f\u6db2\u6027\u817a\u764c\u306b\u304a\u3051\u308bPET\/CT\u3067\u306eFDG\u96c6\u7a4d\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e. JSAWI2015, 16th Annual Symposium (2015.9, \u6de1\u8def)
    \n47.\u6a2a\u4e95\u656c\u5f18, \u7530\u908a\u88d5\u8cb4, \u57ce\u6238\u8f1d\u4ec1, \u5009\u7530\u8056, \u6cb3\u91ce\u73e0\u7f8e, \u4e0a\u8c37\u6643\u7531, \u5927\u6728\u5143\u660e\u7fa9, \u6a9c\u57a3\u5bdb\u7537. Myocardial Blood Flow (MBF) \u306b\u3088\u308b\u6a5f\u80fd\u7684\u6709\u610f\u72ed\u7a84\u75c5\u5909\u306e\u8a3a\u65ad\u80fd\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e\uff1aFractional Flow Reserve (FFR) \u3068\u306e\u6bd4\u8f03. \u7b2c63\u56de\u65e5\u672c\u5fc3\u81d3\u75c5\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a (2015.9, \u6a2a\u6d5c)
    \n48.\u9e7f\u5cf6 \u6587,\u3000\u5ddd\u6761\u6587\u9686, \u6771\u91ce \u535a, \u963f\u90e8\u5145\u4f2f, \u4ed6. \u30a2\u30c6\u30ce\u30b7\u30f3\u8ca0\u8377\u306b\u304a\u3051\u308b\u30ab\u30d5\u30a7\u30a4\u30f3\u5236\u9650\u306f\u8ca0\u8377\u524d12\u6642\u9593\u3067\u5341\u5206\u306a\u306e\u304b? – 24\u6642\u9593\u5236\u9650\u3068\u306e\u6bd4\u8f03 – \u7b2c63\u56de\u65e5\u672c\u5fc3\u81d3\u75c5\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff082015.9, \u6a2a\u6d5c\uff09
    \n49.\u5ddd\u6761\u6587\u9686, \u9e7f\u5cf6 \u6587, \u6771\u91ce \u535a, \u963f\u90e8\u5145\u4f2f, \u4ed6. \u5b89\u9759\u30bf\u30ea\u30a6\u30e0\u5fc3\u7b4b\u8840\u6d41\u30b7\u30f3\u30c1\u30af\u30e9\u30d5\u30a3\u30fc\u30685\u6642\u9593\u5f8c\u9045\u5ef6\u50cf\u3092\u7528\u3044\u305f\u865a\u8840\u5fc3\u7b4b\u8a55\u4fa1\u306e\u6709\u7528\u6027. \u7b2c63\u56de\u65e5\u672c\u5fc3\u81d3\u75c5\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff082015.9, \u6a2a\u6d5c\uff09
    \n50.\u7530\u908a\u88d5\u8cb4, \u57ce\u6238\u8f1d\u4ec1, \u6a2a\u4e95\u656c\u5f18, \u6cb3\u91ce\u73e0\u7f8e, \u4e0a\u8c37\u6643\u7531, \u5009\u7530 \u8056, \u5927\u6728\u5143\u660e\u7fa9, \u6a9c\u57a3\u5be6\u7537, \u671b\u6708\u8f1d\u4e00. \u5fc3\u81d3CT\u3092\u7528\u3044\u305f\u5de6\u5ba4\u5fc3\u7b4b\uff13D maximum principal strain\u306e\u6897\u585e\u5fc3\u7b4b\u691c\u51fa\u306b\u304a\u3051\u308b\u6709\u7528\u6027\u306b\u3064\u3044\u3066\uff1a\u9045\u5ef6\u9020\u5f71MRI\u3068\u6bd4\u8f03\u3057\u3066. \u7b2c63\u56de\u65e5\u672c\u5fc3\u81d3\u75c5\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff082015.9, \u6a2a\u6d5c\uff09
    \n51.\u68ee \u5343\u5c0b, \u4e09\u6728 \u5747, \u677e\u7530 \u6075, \u77f3\u4e38\u826f\u5e83, \u83ca\u6c60\u9686\u5fb3, \u4e95\u4e0a \u6b66, \u5ca1\u672c\u61b2\u7ae0, \u6cb3\u91ce\u517c\u4e45. \u6025\u6027\u671f\u8133\u6897\u585e\u306b\u304a\u3051\u308bArterial spin labeling (ASL) \u306e\u6709\u7528\u6027\u2015Arterial transit artifact\u306e\u691c\u8a0e\u2015
    \n\u7b2c43\u56de\u65e5\u672c\u78c1\u6c17\u5171\u9cf4\u6838\u533b\u5b66\u5927\u4f1a\uff082015.9, \u6771\u4eac\uff09
    \n52.\u6a2a\u4e95\u656c\u5f18, \u7530\u908a\u88d5\u8cb4, \u57ce\u6238\u8f1d\u4ec1, \u798f\u5c71\u76f4\u7d00, \u5c0f\u5ddd\u907c, \u897f\u5c71\u9999\u5b50, \u57ce\u6238\u502b\u4e4b, \u5009\u7530\u8056, \u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. Sampling Rate\u3092\u843d\u3068\u3057\u305fMyocardial Blood Flow (MBF) \u306b\u95a2\u3059\u308b\u691c\u8a0e. \u7b2c9\u56deSCCT\u7814\u7a76\u4f1a (2015.9, \u6771\u4eac)
    \n53.\u798f\u5c71\u76f4\u7d00, \u57ce\u6238\u8f1d\u4ec1, \u6a2a\u4e95\u656c\u5f18, \u5c0f\u5ddd \u907c, \u7530\u908a\u88d5\u8cb4, \u7530\u4ee3\u3089\u307f, \u57ce\u6238\u502b\u4e4b, \u5009\u7530 \u8056, \u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. \u51a0\u52d5\u8108\u652f\u914d\u704c\u6d41\u57df\u89e3\u6790\u30bd\u30d5\u30c8\u3068\u30c0\u30a4\u30ca\u30df\u30c3\u30afCT\u30d1\u30fc\u30d5\u30e5\u30fc\u30b8\u30e7\u30f3\u3092\u7528\u3044\u305f\u5fc3\u7b4b\u8840\u6d41\u91cf\u306b\u304b\u3093\u3059\u308b\u691c\u8a0e. \u7b2c\uff19\u56deSCCT\u7814\u7a76\u4f1a\uff082015.9, \u6771\u4eac\uff09
    \n54.\u53ea\u4fe1\u7f8e\u7d00, \u7d30\u5ddd\u6d69\u5e73, \u68b6\u539f \u8aa0, \u6e05\u6c34\u8f1d\u5f66, \u9ad8\u6a4b\u5fe0\u7ae0, \u9152\u4e95\u4f38\u4e5f, \u83c5\u539f\u656c\u6587, \u672b\u4e45 \u5f18, \u5c71\u4e0b\u7d20\u5f18, \u5bfa\u672c\u5178\u5f18. CEA\u9ad8\u5024\u3092\u793a\u3057\u80ba\u764c\u80f8\u58c1\u6d78\u6f64\u3068\u8853\u524d\u8a3a\u65ad\u3055\u308c\u305f\u60aa\u6027\u80f8\u819c\u4e2d\u76ae\u816b\u306e1\u4f8b. \u7b2c29\u56de\u80f8\u90e8\u653e\u5c04\u7dda\u7814\u7a76\u4f1a\uff082015.10, \u76db\u5ca1\uff09
    \n55.\u4e95\u624b\u9999\u5948\uff0e\u5c0f\u5150\u306b\u767a\u751f\u3057\u305f\u80f8\u8154\u5185Ewing\u8089\u816b\u30d5\u30a1\u30df\u30ea\u30fc\u816b\u760d\u306e1\u4f8b\uff0e\u7b2c29\u56de\u80f8\u90e8\u653e\u5c04\u7dda\u7814\u7a76\u4f1a\uff082015.10, \u76db\u5ca1\uff09
    \n56.\u6e05\u6c34\u8f1d\u5f66, \u53ea\u4fe1\u7f8e\u7d00, \u897f\u5cf6\u7d00\u5b50, \u7d30\u5ddd\u6d69\u5e73, \u68b6\u539f \u8aa0, \u9ad8\u6a4b\u5fe0\u7ae0, \u9152\u4e95\u4f38\u4e5f, \u83c5\u539f\u656c\u6587, \u6e05\u85e4\u4f50\u77e5\u5b50, \u9ad8\u6a4b\u4e09\u5948, \u9ad8\u5d8b\u6210\u8f1d, \u9752\u5100\u5065\u4e8c\u90ce, \u5927\u4f4f\u7701\u4e09, \u897f\u6751\u7406\u6075\u5b50. \u9020\u5f71MRI\u3092\u7528\u3044\u305f\u4e73\u764c\u8853\u524d\u5316\u5b66\u7642\u6cd5\u306e\u6cbb\u7642\u52b9\u679c\u5224\u5b9a\uff1aFDG-PET\/CT\u3068\u306e\u6bd4\u8f03. \u7b2c51\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u79cb\u5b63\u81e8\u5e8a\u5927\u4f1a\uff082015.10, \u76db\u5ca1\uff09
    \n57.\u68b6\u539f \u8aa0, \u7d30\u5ddd\u6d69\u5e73, \u6e05\u6c34\u8f1d\u5f66, \u9ad8\u6a4b\u5fe0\u7ae0, \u9152\u4e95\u4f38\u4e5f, \u83c5\u539f\u656c\u6587, \u672b\u4e45 \u5f18, \u5bfa\u672c\u5178\u5f18. \u591a\u623f\u6027\u80f8\u817a\u56a2\u80de\u306e5\u4f8b. \u7b2c51\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u79cb\u5b63\u81e8\u5e8a\u5927\u4f1a\uff082015.10, \u76db\u5ca1\uff09
    \n58.\u4e2d\u5cf6\u76f4\u7f8e, \u7530\u53e3\u5343\u8535, \u795e\u5d0e\u535a\u5141, \u8d8a\u667a\u8a89\u53f8, \u671b\u6708\u8f1d\u4e00. \u9ad8\u7dda\u91cf\u7387\u8154\u5185\u7167\u5c04\u306b\u304a\u3051\u308b\u7dda\u5f62\u30dc\u30eb\u30c4\u30de\u30f3\u8f38\u9001\u65b9\u7a0b\u5f0f\u3092\u7528\u3044\u305f\u7dda\u91cf\u8a08\u7b97\u30a2\u30eb\u30b4\u30ea\u30ba\u30e0\u306b\u3088\u308b\u7dda\u91cf\u8a55\u4fa1\u306e\u691c\u8a0e. \u7b2c51\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u79cb\u5b63\u81e8\u5e8a\u5927\u4f1a\uff082015.10, \u76db\u5ca1\uff09
    \n59.\u6ff1\u672c \u6cf0, \u897f\u5d0e \u7d71, \u974d\u5ca1\u614e\u592a\u90ce, \u6b66\u7530\u82f1\u6a39, \u771f\u934b\u4fca\u6cbb. \u5b9a\u4f4d\u7167\u5c04\u306e\u6669\u671f\u6709\u5bb3\u4e8b\u8c61\u3068\u3057\u3066\u56a2\u80de\u5f62\u6210\u3092\u6765\u3057\u305f\u814e\u764c\u8133\u8ee2\u79fb\u306e\uff11\u4f8b. \u7b2c51\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u79cb\u5b63\u81e8\u5e8a\u5927\u4f1a\uff082015.10, \u76db\u5ca1\uff09
    \n60.\u677e\u7530 \u6075, \u4e09\u6728\u5747, \u4e95\u4e0a \u6b66, \u83ca\u6c60\u9686\u5fb3, \u77f3\u4e38\u826f\u5e83, \u6751\u4e0a\u5fe0\u53f8, \u68ee \u5343\u5c0b, \u5ddd\u53e3\u76f4\u4eba. Dual energy CT\u3092\u7528\u3044\u3066\u64ae\u50cf\u3055\u308c\u305fdynamic CT\u3067\u306e\u809d\u7d30\u80de\u764c\u306e\u63cf\u51fa\u306b\u304a\u3051\u308b\u4f4e\u96fb\u5727\u64ae\u5f71\u306e\u6709\u7528\u6027. \u7b2c51\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u79cb\u5b63\u81e8\u5e8a\u5927\u4f1a\uff082015.10, \u76db\u5ca1\uff09
    \n61.\u6700\u4e0a \u535a, \u83c5\u539f\u793c\u5b50, \u5ddd\u4e0a\u58fd\u662d, \u305d\u306e\u4ed6. CAD\u304c\u6307\u6458\u3057\u3066\u3044\u305f\u306b\u3082\u95a2\u308f\u3089\u305a\u3001\u7cbe\u691c\u4e0d\u8981\u3068\u5224\u5b9a\u3055\u308c\u305f\u4e73\u304c\u3093\u306e\u691c\u8a0e. \u7b2c25\u56de\u65e5\u672c\u4e73\u764c\u691c\u8a3a\u5b66\u4f1a\u7dcf\u4f1a\uff082015.10, \u3064\u304f\u3070\uff09
    \n62.\u6ff1\u672c \u6cf0, \u974d\u5ca1\u614e\u592a\u90ce, \u6b66\u7530\u82f1\u6a39, \u771f\u934b\u4fca\u6cbb. \u5207\u9664\u4e0d\u80fd\u5c40\u6240\u9032\u884c\u81b5\u764c\u304a\u3088\u3073\u8853\u5f8c\u5c40\u6240\u518d\u767a\u81b5\u764c\u306b\u5bfe\u3059\u308b\u653e\u5c04\u7dda\u6cbb\u7642\u306e\u7d4c\u9a13. \u65e5\u672c\u764c\u6cbb\u7642\u5b66\u4f1a\u7b2c53\u56de\u5b66\u8853\u96c6\u4f1a\uff082015.10, \u4eac\u90fd\uff09
    \n63.\u6c60\u6c34\u6681\u5f66, \u5ddd\u6761\u6587\u9686, \u6771\u91ce\u3000\u535a, \u963f\u90e8\u5145\u4f2f, \u4ed6. \u9ad8\u5ea6\u77f3\u7070\u5316\u75c7\u4f8b\u306e\u51a0\u52d5\u8108\u77f3\u7070\u5316\u6307\u6570\u306b
    \n\u3088\u308b\u30ea\u30b9\u30af\u5c64\u5225\u5316\u306f\u53ef\u80fd\u304b? \u7b2c56\u56de\u65e5\u672c\u8108\u7ba1\u5b66\u4f1a\u4f1a\uff082015.10, \u6771\u4eac\uff09
    \n64\u83c5\u539f\u656c\u6587, \u53ea\u4fe1\u7f8e\u7d00, \u7d30\u5ddd\u6d69\u5e73, \u68b6\u539f \u8aa0, \u6e05\u6c34\u8f1d\u5f66, \u9ad8\u6a4b\u5fe0\u7ae0, \u9152\u4e95\u4f38\u4e5f. \u81b5\u7ba1\u5185\u4e73\u982d\u7c98\u6db2\u6027\u816b\u760d\u306b\u304a\u3051\u308bFDG-PET\/CT-\u56fd\u969b\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u3068\u306e\u6bd4\u8f03-. \u7b2c55\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff082015.11, \u6771\u4eac\uff09
    \n65.\u5c0f\u91ce\u525b\u53f2, \u9152\u4e95\u4f38\u4e5f, \u83c5\u539f\u656c\u6587. \u6838\u533b\u5b66\u691c\u67fb\u306b\u304a\u3051\u308b\u88ab\u3070\u304f\u7dda\u91cf\u63a8\u5b9a\u30b7\u30fc\u30c8\u306e\u4f5c\u6210. \u7b2c55\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff082015.11, \u6771\u4eac\uff09
    \n66.\u53ea\u4fe1\u7f8e\u7d00, \u83c5\u539f\u656c\u6587, \u9152\u4e95\u4f38\u4e5f, \u9ad8\u6a4b\u5fe0\u7ae0, \u6e05\u6c34\u8f1d\u5f66, \u68b6\u539f \u8aa0, \u7d30\u5ddd\u6d69\u5e73, \u897f\u5cf6\u7d00\u5b50. FDG\u96c6\u7a4d\u5897\u52a0\u3092\u793a\u3057\u305f\u826f\u6027\u81b5\u7ba1\u5185\u4e73\u982d\u7c98\u6db2\u6027\u816b\u760d\u306e2\u4f8b. \u7b2c55\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff082015.11, \u6771\u4eac\uff09
    \n67.\u9152\u4e95\u4f38\u4e5f, \u83c5\u539f\u656c\u6587, \u9ad8\u6a4b\u5fe0\u7ae0, \u6e05\u6c34\u8f1d\u5f66, \u68b6\u539f \u8aa0, \u7d30\u5ddd\u6d69\u5e73. \u60aa\u6027\u30ea\u30f3\u30d1\u816b\u6cbb\u7642\u52b9\u679c\u5224\u5b9a\u6642\u306b\u8179\u90e8\u306b\u898b\u3089\u308c\u308b\u826f\u6027FDG\u96c6\u7a4d\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e. \u7b2c55\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff082015.11, \u6771\u4eac\uff09
    \n78.\u897f\u5cf6\u7d00\u5b50, \u83c5\u539f\u656c\u6587, \u53ea\u4fe1\u7f8e\u7d00, \u7d30\u5ddd\u6d69\u5e73, \u68b6\u539f \u8aa0, \u6e05\u6c34\u8f1d\u5f66, \u9ad8\u6a4b\u5fe0\u7ae0, \u9152\u4e95\u4f38\u4e5f. \u9ad8\u5ea6\u306eFDG\u96c6\u7a4d\u3092\u8a8d\u3081\u305f\u9aa8\u5316\u6027\u7b4b\u708e\u306e1\u4f8b. \u7b2c55\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff082015.11, \u6771\u4eac\uff09
    \n69.\u7530\u4ee3\u3089\u307f, \u5bae\u5ddd\u6b63\u7537, \u897f\u5c71\u9999\u5b50, \u6a2a\u4e95\u656c\u5f18, \u5c0f\u5ddd \u907c, \u7530\u908a\u88d5\u8cb4, \u798f\u5c71\u76f4\u7d00, \u57ce\u6238\u502b\u4e4b, \u57ce\u6238\u8f1d\u4ec1, \u5009\u7530 \u8056, \u671b\u6708\u8f1d\u4e00. IgG4\u95a2\u9023\u75be\u60a3\u306eF-18 FDG PET\/CT\u306b\u304a\u3051\u308b\u96c6\u7a4d\u306b\u3064\u3044\u3066. \u7b2c55\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a \uff082015.11, \u6771\u4eac\uff09
    \n70.\u5bae\u5ddd\u6b63\u7537, \u77f3\u6751\u96bc\u4eba, \u897f\u5c71\u9999\u5b50, \u7530\u4ee3\u3089\u307f, \u671b\u6708\u8f1d\u4e00. \u30b7\u30f3\u30dd\u30b8\u30a6\u30e02\u3000\u5fc3\u81d3\u5c02\u7528\u534a\u5c0e\u4f53\u30ac\u30f3\u30de\u30ab\u30e1\u30e9\u306e\u9032\u5c55\u300c\u534a\u5c0e\u4f53SPECT\u88c5\u7f6e\uff1a DiscoveryNM530c\u3092\u7528\u3044\u305fI-123 MIBG\u5fc3\u7e26\u9694\u6bd4\u306e\u6e2c\u5b9a\u300d \u7b2c55\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a \uff082015.11, \u6771\u4eac\uff09
    \n71.\u671b\u6708\u8f1d\u4e00, \u5bae\u5ddd\u6b63\u7537. \u5408\u540c\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u3000\u3068\u3082\u306b\u4f38\u3070\u3059\u6838\u533b\u5b66\uff1a\u5404\u8077\u7a2e\u306e\u6838\u533b\u5b66\u8a3a\u7642\u3078\u306e\u53d6\u308a\u7d44\u307f\u300c\u6838\u533b\u5b66\u5c02\u9580\u533b\u3068\u3057\u3066\u300d \u7b2c55\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a \uff082015.11, \u6771\u4eac\uff09
    \n72.\u4e2d\u5d8b\u61b2\u4e00, \u767e\u702c \u6e80, \u677e\u672c\u76f4\u4e5f, \u7b20\u4e95\u7763\u96c4, \u6728\u66fd\u5553\u7950, \u5bae\u5ddd\u6b63\u7537, \u4ed6. \u30ef\u30fc\u30ad\u30f3\u30b0\u30b0\u30eb\u30fc\u30d7\u5831\u544a\u300c\u5fc3\u81d3\u6838\u533b\u5b66\u306b\u304a\u3051\u308b\u5171\u6709\u30c7\u30fc\u30bf\u30d9\u30fc\u30b9\u306e\u4f5c\u6210\u3068\u30bd\u30d5\u30c8\u30a6\u30a7\u30a2\u9593\u306e\u8f03\u6b63\u300d \u7b2c55\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a \uff082015.11, \u6771\u4eac\uff09
    \n73.\u5ddd\u53e3\u76f4\u4eba, \u83ca\u6c60\u9686\u5fb3, \u77f3\u4e38\u826f\u5e83, \u4e95\u4e0a \u6b66, \u4e09\u6728 \u5747. N-13\u30a2\u30f3\u30e2\u30cb\u30a2PET\u5b9a\u91cf\u5024\u306e\u5c40\u6240\u89e3\u6790\u306b\u3088\u308b\u51a0\u52d5\u8108\u6709\u610f\u72ed\u7a84\u75c5\u5909\u306e\u691c\u51fa\u80fd. \u7b2c55\u56de\u65e5\u672c\u6838\u533b\u5b66\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff082015.11, \u6771\u4eac\uff09
    \n74.\u6ff1\u672c \u6cf0, \u8896\u5ca1\u7d00\u5b5d, \u7a32\u7530\u5b8f\u898f, \u6817\u6797\u4f51\u591a, \u4e2d\u5c71\u91cd\u6a39, \u6850\u5c71\u54f2\u4e00. How much margins are needed to cover the deformity of the prostate\/seminal vesicle in fiducial-marker tracking radiotherapy for prostate cancer? \u65e5\u672c\u653e\u5c04\u7dda\u816b\u760d\u5b66\u4f1a\u7b2c28\u56de\u5b66\u8853\u5927\u4f1a\uff082015.11, \u524d\u6a4b\uff09
    \n75.Kanzaki H, Kataoka M, Nishijima N, Nagasaki K, Uwatsu K, Nishikawa A. Difference in Prognostic Significance of Early Tumor Regression among Histological Subtypes in Stage III Non-Small-Cell Lung Cancer Patients Underwent Definitive Radiotherapy. \u65e5\u672c\u653e\u5c04\u7dda\u816b\u760d\u5b66\u4f1a\u7b2c28\u56de\u5b66\u8853\u5927\u4f1a\uff082015.11, \u524d\u6a4b\uff09
    \n76.\u5927\u67f3\u6587\u5f66, \uff08\u5c0f\u585a\u62d3\u6d0b, \u702c\u6238\u8cb4\u53f8, \u6e05\u6c34\u7d14\u4e00, \u4f50\u3005\u6728\u667a\u6210\uff09, \u7247\u5ca1\u6b63\u660e\u3000\u4ed6. A randomized phase II study of S-1\/CDDP vs. VNR\/CDDP with concurrent RT for locally advanced NSCLC: WJOG5008. \u7b2c56\u56de\u65e5\u672c\u80ba\u304c\u3093\u5b66\u4f1a\uff082015.11, \u6a2a\u6d5c\uff09
    \n    <\/a>\u25cf<\/span> \u56fd\u5185\u5b66\u4f1a\uff08\u5730\u65b9\u4f1a\uff09<\/p>\n
      \n1.\u5ddd\u53e3\u76f4\u4eba, \u57ce\u6238\u8f1d\u4ec1, \u671b\u6708\u8f1d\u4e00. \u5c0f\u5150\u5fc3\u81d3CT\u306e\u64ae\u50cf\u65b9\u6cd5 -Double injection method\u3092\u7528\u3044\u305f\u8a66\u307f- \u7b2c11\u56de\u611b\u5a9b\u5c0f\u5150\u5fc3\u75be\u60a3\u61c7\u8a71\u4f1a\uff082015.2, \u677e\u5c71\uff09
      \n2.\u5ddd\u53e3\u76f4\u4eba, \u83ca\u6c60\u9686\u5fb3, \u798f\u5c71\u76f4\u7d00, \u57ce\u6238\u8f1d\u4ec1, \u671b\u6708\u8f1d\u4e00, \u4ed6. N-13\u30a2\u30f3\u30e2\u30cb\u30a2PET\u3068\u5fc3\u81d3CT\u306b\u3088\u308b\u51a0\u52d5\u8108\u652f\u914d\u704c\u6d41\u57df\u89e3\u6790\u30bd\u30d5\u30c8\u30a6\u30a7\u30a2\u3092\u7528\u3044\u305f\u5fc3\u7b4b\u865a\u8840\u9818\u57df\u306e\u5b9a\u6027\u30fb\u5b9a\u91cf\u8a55\u4fa1. \u7b2c32\u56de\u305b\u3068\u3046\u3061\u5fc3\u81d3CT\u30fbMR\u52c9\u5f37\u4f1a\uff082015.3, \u677e\u5c71\uff09
      \n3.\u4e09\u6728\u3000\u5747. \u6c34\u982d\u75c7\u306e1\u4f8b. \u7b2c20\u56de\u4e2d\u56fd\u30fb\u56db\u56fdNR\u7814\u7a76\u4f1a\uff082015.5, \u5ca1\u5c71\uff09
      \n4.\u53ea\u4fe1\u7f8e\u7d00, \u897f\u5cf6\u7d00\u5b50, \u7d30\u5ddd\u6d69\u5e73, \u68b6\u539f \u8aa0, \u6e05\u6c34\u8f1d\u5f66, \u9ad8\u6a4b\u5fe0\u7ae0, \u9152\u4e95\u4f38\u4e5f, \u83c5\u539f\u656c\u6587. \u80f8\u817a\u30ea\u30f3\u30d1\u4e0a\u76ae\u816b\u69d8\u764c\u306e1\u4f8b. \u7b2c124\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff082015.6, \u5c71\u53e3\uff09
      \n5.\u974d\u5ca1\u614e\u592a\u90ce, \u6ff1\u672c \u6cf0, \u6b66\u7530\u82f1\u6a39, \u771f\u934b\u4fca\u6cbb, \u4ed6. \u8179\u8154\u5185\u51fa\u8840\u3092\u6765\u3057\u305f\u80c3GIST\u306e\u7834\u88c2\u306e\uff11\u4f8b. \u7b2c124\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff082015.6, \u5c71\u53e3\uff09
      \n6.\u795e\ufa11\u535a\u5145, \u7247\u5ca1\u6b63\u660e, \u897f\u5cf6\u7d00\u5b50, \u9577\ufa11 \u6167, \u4e0a\u6d25\u5b5d\u592a\u90ce, \u897f\u5ddd \u6566. III\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306b\u5bfe\u3059\u308b\u653e\u5c04\u7dda\u6cbb\u7642\u306b\u3064\u3044\u3066\u8089\u773c\u7684\u816b\u760d\u5bb9\u7a4d\u306e\u4e88\u5f8c\u306b\u53ca\u307c\u3059\u5f71\u97ff\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e. \u7b2c124\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff082015.6, \u5c71\u53e3\uff09
      \n7.\u897f\u5cf6\u7d00\u5b50, \u7247\u5ca1\u6b63\u660e, \u897f\u5ddd \u6566, \u4e0a\u6d25\u5b5d\u592a\u90ce, \u795e\ufa11\u535a\u5145, \u9577\ufa11 \u6167. \u5b50\u5bae\u9838\u764c\u306b\u5bfe\u3059\u308bIGBT\u306b\u304a\u3051\u308b\u8154\u5185\u7167\u5c04\u524dMRI\u3092\u7528\u3044\u305f\u8089\u773c\u7684\u816b\u760d\u5bb9\u7a4d\u306b\u95a2\u3059\u308b\u691c\u8a0e. \u7b2c124\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff082015.6, \u5c71\u53e3\uff09
      \n8.\u6ff1\u672c \u6cf0, \u7a32\u7530\u5b8f\u898f, \u6817\u6797\u4f51\u591a, \u6850\u5c71\u54f2\u4e00, \u974d\u5ca1\u614e\u592a\u90ce, \u6b66\u7530\u82f1\u6a39, \u771f\u934b\u4fca\u6cbb, \u591a\u7530\u9756\u5f18, \u4e39\u53f8 \u671b, \u83ca\u5ddd\u5fe0\u5f66. \u524d\u7acb\u817a\u764c\u30b5\u30a4\u30d0\u30fc\u30ca\u30a4\u30d5\u6cbb\u7642\u306e\u521d\u671f\u7d4c\u9a13. \u7b2c124\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff082015.6, \u5c71\u53e3\uff09
      \n9.\u7d30\u5ddd\u6d69\u5e73, \u53ea\u4fe1\u7f8e\u7d00, \u897f\u5cf6\u7d00\u5b50, \u68b6\u539f \u8aa0, \u6e05\u6c34\u8f1d\u5f66, \u9ad8\u6a4b\u5fe0\u7ae0, \u9152\u4e95\u4f38\u4e5f, \u83c5\u539f\u656c\u6587, \u897f\u6751\u7406\u6075\u5b50, \u6e05\u85e4\u4f50\u77e5\u5b50, \u5927\u4f4f\u7701\u4e09. \u30c8\u30ea\u30d7\u30eb\u30cd\u30ac\u30c6\u30a3\u30d6\u4e73\u764c\u8853\u524d\u5316\u5b66\u7642\u6cd5\u306e\u52b9\u679c\u5224\u5b9a\u3068\u4e88\u5f8c\u4e88\u6e2c – FDG-PET\/CT\u306b\u3088\u308b\u691c\u8a0e -. \u7b2c50\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a (2015.6, \u5c71\u53e3)
      \n10.\u6a2a\u4e95\u656c\u5f18, \u7530\u908a\u88d5\u8cb4, \u57ce\u6238\u8f1d\u4ec1, \u5c0f\u5ddd \u907c, \u798f\u5c71\u76f4\u7d00, \u7530\u4ee3\u3089\u307f, \u897f\u5c71\u9999\u5b50, \u57ce\u6238\u502b\u4e4b, \u5009\u7530 \u8056, \u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. Sampling Rate\u3092\u843d\u3068\u3057\u305fMyocardial Blood Flow (MBF) \u306b\u95a2\u3059\u308b\u691c\u8a0e. \u7b2c32\u56de\u3057\u307e\u306a\u307f\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9 (2015.10, \u4eca\u6cbb)
      \n11.\u798f\u5c71\u76f4\u7d00, \u57ce\u6238\u8f1d\u4ec1, \u6a2a\u4e95\u656c\u5f18, \u5c0f\u5ddd \u907c, \u7530\u908a\u88d5\u8cb4, \u7530\u4ee3\u3089\u307f, \u57ce\u6238\u502b\u4e4b, \u5009\u7530 \u8056, \u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. \u51a0\u52d5\u8108\u652f\u914d\u704c\u6d41\u57df\u89e3\u6790\u30bd\u30d5\u30c8\u3068\u30c0\u30a4\u30ca\u30df\u30c3\u30afCT\u30d1\u30fc\u30d5\u30e5\u30fc\u30b8\u30e7\u30f3\u3092\u7528\u3044\u305f\u5fc3\u7b4b\u8840\u6d41\u91cf\u306b\u95a2\u3059\u308b\u691c\u8a0e\uff0e\u7b2c33\u56de\u305b\u3068\u3046\u3061\u5fc3\u81d3CT\/MRI\u7814\u7a76\u4f1a\uff082015.10, \u5e83\u5cf6\uff09
      \n12.\u5c0f\u5ddd \u907c, \u57ce\u6238\u502b\u4e4b, \u6a2a\u4e95\u656c\u5f18, \u798f\u5c71\u76f4\u7d00, \u7530\u908a\u88d5\u8cb4, \u7530\u4ee3\u3089\u307f, \u57ce\u6238\u8f1d\u4ec1, \u5009\u7530 \u8056, \u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. \u9673\u65e7\u6027\u5fc3\u7b4b\u6897\u585e\u306b\u304a\u3051\u308b Feature-tracking cardiovascular magnetic resonance\u3092\u7528\u3044\u305fCircumferential Strain\u5206\u6790. \u7b2c33\u56de\u305b\u3068\u3046\u3061\u5fc3\u81d3CT\/MRI\u7814\u7a76\u4f1a\uff082015.10, \u5e83\u5cf6\uff09
      \n13.\u5ddd\u53e3\u76f4\u4eba, \u77f3\u4e38\u826f\u5e83, \u6751\u4e0a\u5fe0\u53f8, \u7530\u4e2d\u5b8f\u660e, \u4e09\u6728 \u5747. \u6c17\u7ba1\u652f\u52d5\u8108\u7624\u306b\u5bfe\u3057\u3066\u30b3\u30a4\u30eb\u585e\u6813\u8853\u3092\u65bd\u884c\u3057\u305f\uff11\u4f8b. \u7b2c29\u56de\u4e2d\u56db\u56fdIVR\u7814\u7a76\u4f1a\uff082015.10, \u5ca1\u5c71\uff09
      \n14.\u6a2a\u4e95\u656c\u5f18, \u4e95\u51fa\u9999\u5948, \u5bae\u5ddd\u6b63\u7537, \u798f\u5c71\u76f4\u7d00, \u7530\u4ee3\u3089\u307f, \u897f\u5c71\u9999\u5b50, \u671b\u6708\u8f1d\u4e00. \u80ba\u591a\u5f62\u764c\u306eFDG-PET\/CT\u6240\u898b\u306b\u95a2\u3059\u308b\u691c\u8a0e. \u611b\u5a9b\u653e\u5c04\u7dda\u79d1\u533b\u4f1a\u7b2c141\u56de\u4f8b\u4f1a (2015.11, \u677e\u5c71)
      \n15.\u5ddd\u53e3\u76f4\u4eba, \u77f3\u4e38\u826f\u5e83, \u6751\u4e0a\u5fe0\u53f8, \u7530\u4e2d\u5b8f\u660e, \u4e09\u6728 \u5747. \u6c17\u7ba1\u652f\u52d5\u8108\u7624\u306b\u5bfe\u3057\u3066\u30b3\u30a4\u30eb\u585e\u6813\u8853\u3092\u65bd\u884c\u3057\u305f\uff11\u4f8b. \u7b2c29\u56de\u4e2d\u56db\u56fdIVR\u7814\u7a76\u4f1a\uff082015.10, \u5ca1\u5c71\uff09
      \n16.\u53ea\u4fe1\u7f8e\u7d00, \u897f\u5cf6\u7d00\u5b50, \u7d30\u5ddd\u6d69\u5e73, \u6850\u5c71\u90c1\u5b50, \u6e05\u6c34\u8f1d\u5f66, \u9ad8\u6a4b\u5fe0\u7ae0, \u9152\u4e95\u4f38\u4e5f, \u83c5\u539f\u656c\u6587, \u767d\u5c71\u88d5\u5b50, \u7af9\u539f\u548c\u5b8f, \u5bfa\u672c\u5178\u5f18. \u4e73\u764c\u5b50\u5bae\u8ee2\u79fb\u306e1\u4f8b. \u7b2c125\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff082015.12, \u9ad8\u77e5\uff09
      \n17.\u897f\u5cf6\u7d00\u5b50, \u53ea\u4fe1\u7f8e\u7d00, \u7d30\u5ddd\u6d69\u5e73, \u6850\u5c71\u90c1\u5b50, \u6e05\u6c34\u8f1d\u5f66, \u9ad8\u6a4b\u5fe0\u7ae0, \u9152\u4e95\u4f38\u4e5f, \u83c5\u539f\u656c\u6587, \u7247\u5ca1\u6b63\u660e, \u843d\u5408\u4eae\u4e8c, \u5c0f\u7560\u8a89\u4e5f, \u6a4b\u6839\u52dd\u7fa9, \u5bfa\u672c\u5178\u5f18. \u8853\u524d\u8a3a\u65ad\u304c\u56f0\u96e3\u3067\u3042\u3063\u305f\u524d\u7acb\u817a\u764c\u8853\u5f8c\u518d\u767a\u306e1\u4f8b. \u7b2c125\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff082015.12, \u9ad8\u77e5\uff09
      \n18.\u974d\u5ca1\u614e\u592a\u90ce, \u6ff1\u672c \u6cf0, \u6b66\u7530\u82f1\u6a39, \u771f\u934b\u4fca\u6cbb, \u4ed6. \u8a3a\u65ad\u306b\u82e6\u616e\u3057\u305f\u81b5\u982d\u90e8\u306e\u591a\u8840\u6027\u816b\u7624\u6027\u75c5\u5909\u306e\uff11\u4f8b. \u7b2c125\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff082015.12, \u9ad8\u77e5\uff09
      \n19.\u5409\u7530\u548c\u6a39, \u7530\u4e2d\u5b8f\u660e, \u6d25\u7530\u5b5d\u6cbb, \u671b\u6708\u8f1d\u4e00, \u4ed6. \u8179\u8154\u52d5\u8108\u306b\u5bfe\u3057\u3066\u30b3\u30a4\u30eb\u585e\u6813\u8853\u3092\u65bd\u884c\u3057\u305f1\u4f8b. \u7b2c125\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff082015.12, \u9ad8\u77e5\uff09
      \n20.\u5e73\u4e95\u90a6\u660e, \u5c0f\u5ddd \u907c, \u57ce\u6238\u502b\u4e4b, \u57ce\u6238\u8f1d\u4ec1, \u671b\u6708\u8f1d\u4e00. \u4e09\u5c16\u5f01\u306b\u767a\u751f\u3057\u305f\u4e73\u982d\u72b6\u7dda\u7dad\u5f3e\u6027\u816b\u306e\u4e00\u4f8b. \u7b2c125\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff082015.12, \u9ad8\u77e5\uff09
      \n21.\u6d77\u8001\u539f\u308b\u3044, \u68b6\u539f \u8aa0, \u6d66\u5cf6\u96c4\u4ecb, \u677e\u7530 \u5065, \u8fd1\u85e4\u7531\u7f8e\u96c4, \u6751\u7530\u7e41\u5229. \u4e0a\u8449\u767a\u751f\u80ba\u5185\u5206\u753b\u75c7\u306e\u4e00\u4f8b. \u7b2c125\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff082015.12, \u9ad8\u77e5\uff09
      \n22.\u5ddd\u53e3\u76f4\u4eba, \u77f3\u5ddd\u6d69\u53f2, \u5bae\u5185\u7b11\u9e97, \u677e\u6728\u5f18\u91cf, \u83ca\u6c60\u9686\u5fb3, \u4e95\u4e0a \u6b66, \u4e09\u6728 \u5747. \u30a2\u30f3\u30e2\u30cb\u30a2PET\u306b\u3088\u308b\u865a\u8840\u6027\u5fc3\u75be\u60a3\u306e\u6cbb\u7642\u52b9\u679c\u306e\u691c\u8a0e. \u7b2c125\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff082015.12, \u9ad8\u77e5\uff09
      \n23.\u9ad8\u9580\u653f\u5609, \u677e\u7530 \u6075, \u77f3\u4e38\u826f\u5e83, \u6751\u4e0a\u5fe0\u53f8, \u68ee\u3000\u5343\u5c0b, \u5916\u7912\u77e5\u6075, \u4e95\u4e0a\u3000\u6b66, \u4e09\u6728\u3000\u5747. A\u578b\u6025\u6027\u5927\u52d5\u8108\u89e3\u96e2\u624b\u8853\u306b\u7528\u3044\u305fGelatin-resorcin-formalin(GRF) glue\u306b\u8d77\u56e0\u3057\u305f\u3068\u8003\u3048\u3089\u308c\u305f\u543b\u5408\u90e8\u52d5\u8108\u7624\u306e2\u4f8b. \u7b2c125\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff082015.12, \u9ad8\u77e5\uff09
      \n24.\u5317\u5ddd \u5bdb, \u7af9\u6cbb \u667a, \u6ff1\u672c \u6cf0\uff0c\u974d\u5ca1\u614e\u592a\u90ce, \u6b66\u7530\u82f1\u6a39, \u771f\u934b\u4fca\u6cbb. \u7de9\u548c\u7167\u5c04\u75c7\u4f8b\u306e\u4e88\u5f8c\u306e\u691c\u8a0e. \u7b2c67\u56de\u4e2d\u56fd\u30fb\u56db\u56fd\u653e\u5c04\u7dda\u6cbb\u7642\u61c7\u8a71\u4f1a\uff082015.12, \u9ad8\u77e5\uff09
      \n      <\/a>\u25a0<\/span> \u8b1b\u6f14<\/strong><\/p>\n
        \n1.\u57ce\u6238\u502b\u4e4b. \u5727\u7e2e\u30bb\u30f3\u30b7\u30f3\u30b0\u3092\u7528\u3044\u305fReal-Time Cardiac Cine MR\u306e\u6709\u7528\u6027. \u7b2c25\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u753b\u50cf\u52d5\u614b\u5b66\u4f1a\u30e9\u30f3\u30c1\u30e7\u30f3\u30bb\u30df\u30ca\u30fc\uff082015.1, \u6771\u4eac\uff09
        \n2.\u57ce\u6238\u8f1d\u4ec1\uff0ePerfusion CT\u3067FFR\u306b\u8feb\u308b. Winter Imaging Conference\u3000\uff082015.1, \u5317\u6d77\u9053\uff09
        \n3.\u5bae\u5ddd\u6b63\u7537. \u30d1\u30cd\u30eb\u30c7\u30a3\u30b9\u30ab\u30c3\u30b7\u30e7\u30f3\u3000\u5faa\u74b0\u5668\u8a3a\u7642\u306b\u304a\u3051\u308b\u30e2\u30c0\u30ea\u30c6\u30a3\u306e\u6700\u8fd1\u306e\u9032\u6b69\uff1b\u534a\u5c0e\u4f53SPECT\u2460\u3000Discovery NM530c. \u7b2c46\u56de\u5fc3\u81d3\u6838\u533b\u5b66\u8ac7\u8a71\u4f1a\uff082015.1, \u6771\u4eac\uff09
        \n4.\u6d25\u7530\u5b5d\u6cbb. \u6025\u6027\u8179\u75c7\u306e\u753b\u50cf\u8a3a\u65ad. \u611b\u5a9b\u770c\u653e\u5c04\u7dda\u6280\u5e2b\u4f1a\uff082015.1, \u677e\u5c71\uff09
        \n5.\u6d25\u7530\u5b5d\u6cbb. CT colonography\u306e\u73fe\u72b6\u3068\u5927\u8178\u764c\u306e\u8a3a\u65ad\u80fd\u306b\u3064\u3044\u3066. CT\u30fbMRI\u7814\u7a76\u4f1a\u611b\u5a9b\uff082015.3, \u677e\u5c71\uff09
        \n6.\u4ec1\u4e95\u7530\u308a\u3061. \u3046\u3064\u75c5\u3068\u8a8d\u77e5\u75c7\u306e\u9451\u5225\u3078\u306eMRI\u306eVBM\u3068DTT\u306e\u6709\u7528\u6027.\u7b2c\uff15\u56de\u4e5d\u5dde\u30a2\u30eb\u30c4\u30cf\u30a4\u30de-\u578b\u8a8d\u77e5\u75c7\u7814\u7a76\u4f1a\uff082015.1, \u798f\u5ca1\uff09
        \n7.\u5bae\u5ddd\u6b63\u7537. \u6559\u80b2\u8b1b\u6f14\u3000\u5fc3\u7b4bSPECT\u306e\u6280\u8853\u3068\u81e8\u5e8a\u5fdc\u7528\u3000\u5fc3\u7b4bSPECT\u5148\u7aef\u6280\u8853\uff1a\u534a\u5c0e\u4f53\u30ab\u30e1\u30e9\u306eInnovative Technology.\u3000\u7b2c40\u56de\u30cb\u30e5\u30fc\u30bf\u30a6\u30f3\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9\uff082015.2\uff0c\u4eac\u90fd\uff09
        \n8.\u4e95\u4e0a \u6b66. \u304c\u3093\u767b\u9332\u306b\u95a2\u3059\u308b\u809d\u81d3\u304c\u3093\u306e\u3059\u3079\u3066\u30fc\u75ab\u5b66\u30fb\u8a3a\u65ad\u30fb\u6cbb\u7642\u30fbTNM\u30fb\u7d44\u7e54\u578b\u30fc \u307f\u3093\u306a\u306e\u305f\u3081\u306e\u4e94\u5927\u304c\u3093\u767b\u9332\u8b1b\u5ea72014\uff082015.2, \u677e\u5c71\uff09
        \n9.\u5bae\u5ddd\u6b63\u7537. \u6559\u80b2\u8b1b\u6f14\u3000\u5fc3\u7b4bSPECT\u306e\u6280\u8853\u3068\u81e8\u5e8a\u5fdc\u7528\u3000\u5fc3\u7b4bSPECT\u5148\u7aef\u6280\u8853\uff1a\u534a\u5c0e\u4f53\u30ab\u30e1\u30e9\u306eInnovative Technology.\u3000\u7b2c40\u56de\u30cb\u30e5\u30fc\u30bf\u30a6\u30f3\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9\uff082015.2\uff0c\u4eac\u90fd\uff09
        \n10.\u4e95\u4e0a \u6b66. \u304c\u3093\u767b\u9332\u306b\u95a2\u3059\u308b\u809d\u81d3\u304c\u3093\u306e\u3059\u3079\u3066\u30fc\u75ab\u5b66\u30fb\u8a3a\u65ad\u30fb\u6cbb\u7642\u30fbTNM\u30fb\u7d44\u7e54\u578b\u30fc \u307f\u3093\u306a\u306e\u305f\u3081\u306e\u4e94\u5927\u304c\u3093\u767b\u9332\u8b1b\u5ea72014\uff082015.2, \u677e\u5c71\uff09
        \n11.\u57ce\u6238\u502b\u4e4b. \u5727\u7e2e\u30bb\u30f3\u30b7\u30f3\u30b0\u304c\u3082\u305f\u3089\u3059\u65b0\u305f\u306a\u9ad8\u901fMRI\u64ae\u50cf. \u7b2c79\u56de\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30e9\u30f3\u30c1\u30e7\u30f3\u30bb\u30df\u30ca\u30fc\uff082015.4, \u5927\u962a\uff09
        \n12.\u57ce\u6238\u8f1d\u4ec1\uff0e\u5fc3\u81d3CT\u306b\u304a\u3051\u308bPhyZiodynamics\u306e\u6709\u7528\u6027. \u7b2c74\u56de\u65e5\u672c\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\u30e9\u30f3\u30c1\u30e7\u30f3\u30bb\u30df\u30ca\u30fc\uff082015.4, \u6a2a\u6d5c\uff09
        \n13.\u4e95\u624b\u9999\u5948. \u30dc\u30ea\u30e5\u30fc\u30e0\u30d3\u30e5\u30fc\u30a2AZE Phoenix\u306e\u81e8\u5e8a\u6d3b\u7528. \u7b2c74\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff082015.4, \u6a2a\u6d5c\uff09
        \n14.\u57ce\u6238\u502b\u4e4b. \u5fc3\u81d3Cine MR\u306e\u73fe\u72b6\u3068\u5727\u7e2e\u30bb\u30f3\u30b7\u30f3\u30b0\u304c\u3082\u305f\u3089\u3059\u65b0\u305f\u306a\u53ef\u80fd\u6027. AIMS Cardiac Imaging 20152015. 5 \u6771\u4eac\uff09
        \n15.\u57ce\u6238\u8f1d\u4ec1\uff0ePerfusion CT\u3092\u7528\u3044\u305f\u5fc3\u7b4b\u865a\u8840\u8a55\u4fa1. AIMS Cardiac Imaging 2015\uff082015.5, \u6771\u4eac\uff09
        \n16.\u57ce\u6238\u8f1d\u4ec1\uff0eCardiac MRI & CT \u2013Current Status and Future Directions. The 2nd Japanese-Korean Joint Meeting of MR Angiography\uff082015.5, Seoul, Korea\uff09
        \n17.\u57ce\u6238\u502b\u4e4b. Compressed sensing\u306b\u3088\u308b\u5fc3\u81d3MRI\u306e\u65b0\u3057\u3044\u5c55\u958b. Advanced CT\uff65MR 2015\uff082015.6, \u9577\u91ce\uff09
        \n18.\u83ca\u6c60\u6075\u4e00. MRI\u306e\u4fe1\u53f7\u5f37\u5ea6\u304b\u3089\u8003\u3048\u308b. \u611b\u5a9bBrain Attack Forum\uff082015.6, \u677e\u5c71\uff09
        \n19.\u5bae\u5ddd\u6b63\u7537. \u6307\u540d\u8b1b\u6f14\u3000\u814e\u7d30\u80de\u304c\u3093\u306e\u753b\u50cf\u8a3a\u65ad -PET\/CT\u306e\u6709\u7528\u6027\u2014\u3000Pfizer RCC Symposium in \u611b\u5a9b\uff082015.6\uff0c\u677e\u5c71\uff09
        \n20.\u677e\u7530 \u6075. \u6559\u80b2\u8b1b\u6f14\u300cdual energy CT\u306b\u3088\u308b\u809d\u764c\u306e\u8a3a\u65ad\u300d \u677e\u5c71\u653e\u5c04\u7dda\u79d1\u533b\u4f1a\u7b2c8\u56de\u4f8b\u4f1a\uff082015.6, \u677e\u5c71\uff09
        \n21.\u5c71\u672c\u5c1a\u5e78. \u653e\u5c04\u7dda\u306e\u57fa\u790e\u3068\u4eba\u4f53\u5f71\u97ff\u306b\u3064\u3044\u3066. \u6ecb\u8cc0\u770c\u7dca\u6025\u88ab\u3070\u304f\u533b\u7642\u4eba\u6750\u80b2\u6210\u7814\u4fee\u4f1a\uff082015.7, \u9577\u6d5c\uff09
        \n22.\u5c71\u672c\u5c1a\u5e78. \u539f\u5b50\u529b\u707d\u5bb3\u533b\u7642\u3001\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u306b\u3064\u3044\u3066. \u6ecb\u8cc0\u770c\u7dca\u6025\u88ab\u3070\u304f\u533b\u7642\u4eba\u6750\u80b2\u6210\u7814\u4fee\u4f1a\uff082015.7, \u9577\u6d5c\uff09
        \n23.\u5c71\u672c\u5c1a\u5e78. \u5b89\u5fc3\u3057\u3066\u88ab\u3070\u304f\u533b\u7642\u306b\u643a\u308f\u308b\u305f\u3081\u306b. \u7b2c\uff11\u56de\u4eac\u90fd\u5927\u5b66\u88ab\u3070\u304f\u533b\u7642\u8b1b\u6f14\u4f1a\uff082015.7, \u4eac\u90fd\uff09
        \n24.\u5c71\u672c\u5c1a\u5e78. \u653e\u5c04\u7dda\u306e\u304a\u306f\u306a\u3057. \u8eab\u306e\u56de\u308a\u306e\u653e\u5c04\u7dda\u6e2c\u5b9a\u4f53\u9a13\u6559\u5ba4\uff082015.7, \u897f\u4e88\uff09
        \n25.\u57ce\u6238\u8f1d\u4ec1\uff0eMyocardial CT Strain Analysis. 10th Annual Scientific meeting of the Society of Cardiac Computed Tomography\uff082015.7, Las Vegas, USA\uff09
        \n26.\u5bae\u5ddd\u6b63\u7537. \u6307\u540d\u8b1b\u6f14\u3000\u534a\u5c0e\u4f53SPECT\u88c5\u7f6e\uff1aDNM 530c\u306b\u3088\u308b\u5fc3\u7b4b\u8840\u6d41\u4e88\u5099\u80fd\u306e\u8a55\u4fa1. \u7b2c47\u56de\u5fc3\u81d3\u6838\u533b\u5b66\u8ac7\u8a71\u4f1a\uff082015.7, \u6771\u4eac\uff09
        \n27.\u5bae\u5ddd\u6b63\u7537. \u7279\u5225\u8b1b\u6f14 \u5fc3\u30b5\u30eb\u30b3\u30a4\u30c9\u30fc\u30b7\u30b9\u306eFDG-PET\u8a3a\u65ad\u306e\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3. \u7b2c21\u56de\u5148\u7aef\u533b\u7528\u753b\u50cf\u7814\u7a76\u4f1a\uff082015.7\uff0c\u795e\u6238\uff09
        \n28.\u4e95\u4e0a \u6b66. \u304c\u3093\u306e\u753b\u50cf\u8a3a\u65ad\u30fc\u753b\u50cf\u8a3a\u65ad\u533b\u306f\u3053\u3046\u8003\u3048\u3066\u3044\u308b\u30fc \u611b\u5a9b\u770c\u7acb\u4e2d\u592e\u75c5\u9662\u516c\u958b\u30bb\u30df\u30ca\u30fc\uff082015.7, \u677e\u5c71\uff09
        \n29.\u57ce\u6238\u502b\u4e4b. \u30a8\u30ad\u30b9\u30d1\u30fc\u30c8\u306e\u305f\u3081\u306e\u6700\u65b0CMR\u6280\u8853 Compressed sensing. SCMR Japan WG Seminar 2015\uff082015.8, \u6771\u4eac\uff09
        \n30.\u57ce\u6238\u502b\u4e4b. Compressed sensing\u3092\u7528\u3044\u305f\u5fc3\u81d3cine MRI. \u753b\u50cf\u8a3a\u65ad\u306e\u6700\u524d\u7dda\uff082015.8, \u611b\u5a9b\uff09
        \n31.\u5009\u7530 \u8056. \u8ca0\u8377CT Perfusion\u306b\u304a\u3051\u308b\u9020\u5f71\u6cd5. \u7b2c9\u56deSCCT\u7814\u7a76\u4f1a\u3000\u6559\u80b2\u30bb\u30c3\u30b7\u30e7\u30f3\uff082015. 9, \u6771\u4eac\uff09
        \n32.\u83c5\u539f\u656c\u6587. FDG-PET\/CT\u8aad\u5f71\u306e\u30d4\u30c3\u30c8\u30d5\u30a9\u30fc\u30eb. \u7b2c6\u56de\u5e83\u5cf6\u816b\u760dPET\u30bb\u30df\u30ca\u30fc\uff082015.9, \u5e83\u5cf6\uff09
        \n33.\u5c71\u672c\u5c1a\u5e78. \u5b89\u5b9a\u30e8\u30a6\u7d20\u5264\u4e8b\u524d\u914d\u5e03\u306b\u95a2\u3059\u308b\u5168\u56fd\u306e\u52d5\u5411\u306b\u3064\u3044\u3066. \uff082015.9, \u67cf\u5d0e\uff09
        \n34.\u5c71\u672c\u5c1a\u5e78. \u6551\u8b77\u6240\u306b\u304a\u3051\u308b\u521d\u671f\u88ab\u3070\u304f\u533b\u7642\u6d3b\u52d5\u306b\u3064\u3044\u3066. \u5e73\u621027\u5e74\u5ea6\u5730\u57df\u4fdd\u5065\u5e2b\u7b49\u7814\u4fee\u4f1a\uff082015.9, \u516b\u5e61\u6d5c\uff09
        \n35.\u57ce\u6238\u502b\u4e4b. Compressed sensing\u304c\u3082\u305f\u3089\u3059\u65b0\u305f\u306a\u5fc3\u81d3MRI. \u7b2c40\u56de\u5357\u4e88\u5faa\u74b0\u5668\u753b\u50cf\u7814\u7a76\u4f1a\uff082015.9, \u611b\u5a9b\uff09
        \n36.\u57ce\u6238\u8f1d\u4ec1\uff0e\u51a0\u52d5\u8108CTA\u306b\u304a\u3051\u308b\u5e0c\u91c8\u9020\u5f71\u6cd5\u306e\u6709\u7528\u6027. SCCT Japan \u6559\u80b2\u30bb\u30c3\u30b7\u30e7\u30f3\uff082015.9, \u6771\u4eac\uff09
        \n37.\u6ff1\u672c \u6cf0. \u80ba\u304c\u3093\u306e\u653e\u5c04\u7dda\u6cbb\u7642\u306b\u3064\u3044\u3066. \u5e02\u6c11\u516c\u958b\u8b1b\u5ea7\uff082015.9, \u4eca\u6cbb\uff09
        \n38.\u5c71\u672c\u5c1a\u5e78. \u653e\u5c04\u7dda\u306e\u4eba\u4f53\u5f71\u97ff\u3068\u798f\u5cf6\u306e\u73fe\u72b6\u306b\u3064\u3044\u3066. \u30e1\u30c7\u30a3\u30ab\u30eb\u30b9\u30bf\u30c7\u30a3\u5354\u4f1a\u7814\u4fee\u4f1a\uff082015.10, \u6771\u4eac\uff09
        \n39.\u5c71\u672c\u5c1a\u5e78. \u539f\u5b50\u529b\u707d\u5bb3\u533b\u7642\u306e\u6982\u8981\u3068\u5404\u5730\u57df\u306e\u5bfe\u5fdc\u72b6\u6cc1. \u96fb\u6e90\u5730\u57df\u632f\u8208\u30bb\u30f3\u30bf\u30fc\u8b1b\u6f14\u4f1a\uff082015.10, \u6771\u4eac\uff09
        \n40.\u5c71\u672c\u5c1a\u5e78. \u88ab\u3070\u304f\u533b\u7642\u306e\u5b9f\u969b \u767a\u707d\u73fe\u5834\u304b\u3089\u533b\u7642\u5bfe\u5fdc\u307e\u3067. \u7b2c\uff12\u56de\u4eac\u90fd\u5927\u5b66\u88ab\u3070\u304f\u533b\u7642\u8b1b\u6f14\u4f1a\uff082015.10, \u4eac\u90fd\uff09
        \n41.Tomoyuki Kido. Present and Future of Cardiac Magnetic Resonance Imaging. Specialized Training in Advances in Radiology 2015\uff082015.10, Nanjing, China\uff09
        \n42.\u57ce\u6238\u502b\u4e4b. \u80a5\u5927\u6027\u5fc3\u7b4b\u75be\u60a3\u306b\u304a\u3051\u308b\u5fc3\u81d3MRI\u306e\u5f79\u5272. \u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1aE learning\uff082015.10, \u5927\u962a\uff09
        \n43.\u57ce\u6238\u8f1d\u4ec1\uff0e\u5fc3\u4e0d\u5168\u306b\u304a\u3051\u308b\u975e\u4fb5\u8972\u7684\u306a\u753b\u50cf\u8a3a\u65ad\u306e\u5f79\u5272. \u611b\u5a9b\u5fc3\u81d3\u6838\u533b\u5b66\u8ac7\u8a71\u4f1a \u6559\u80b2\u8b1b\u6f14\uff082015.10, \u677e\u5c71\uff09
        \n44.\u57ce\u6238\u8f1d\u4ec1\uff0ePerfusion CT\u3092\u7528\u3044\u305f\u5fc3\u7b4b\u865a\u8840\u8a55\u4fa1\u306e\u6709\u7528\u6027\u3068\u5c06\u6765\u5c55\u671b. \u90a3\u9808Perfusion CT meeting\uff082015.10, \u6803\u6728\uff09
        \n45.\u57ce\u6238\u8f1d\u4ec1\uff0eStenosis Detection and Quantification by CT\u3001European Society of Cardiac Radiology\uff082015.10, Vienna, Austria\uff09
        \n46.\u5bae\u5ddd\u6b63\u7537. \u7279\u5225\u8b1b\u6f14 \u5fc3\u30b5\u30eb\u30b3\u30a4\u30c9\u30fc\u30b7\u30b9\u306ePET\u8a3a\u65ad\u30fb\u534a\u5c0e\u4f53\u5fc3\u7b4bSPECT\u306e\u81e8\u5e8a. \u7b2c21\u56de\u5fc3\u81d3\u6838\u533b\u5b66\u61c7\u8a71\u4f1a\uff082015.10\uff0c\u90e1\u5c71\uff09
        \n47.\u5c71\u672c\u5c1a\u5e78. \u7dca\u6025\u88ab\u3070\u304f\u533b\u7642\u306e\u57fa\u790e\u306b\u3064\u3044\u3066. \u5e73\u621027\u5e74\u5ea6\u6ecb\u8cc0\u770c\u85ac\u5264\u5e2b\u4f1a\u707d\u5bb3\u533b\u7642\u7814\u4fee\u4f1a\uff082015.11, \u9577\u6d5c\uff09
        \n48.\u5c71\u672c\u5c1a\u5e78. \u539f\u5b50\u529b\u707d\u5bb3\u6642\u306e\u653e\u5c04\u7dda\u7ba1\u7406\u58eb\u306e\u6d3b\u52d5. \u7b2c31\u56de\u65e5\u672c\u8a3a\u7642\u653e\u5c04\u7dda\u6280\u5e2b\u5b66\u8853\u5927\u4f1a\u653e\u5c04\u7dda\u7ba1\u7406\u58eb\u5206\u79d1\u4f1a\uff082015.11, \u4eac\u90fd\uff09
        \n49.\u4e2d\u5cf6\u76f4\u7f8e. \u6559\u80b2\u8b1b\u6f14 \u4e73\u817a\u57fa\u790e\u7de8\u3000\u65e5\u672c\u653e\u5c04\u7dda\u816b\u760d\u5b66\u4f1a\u3000\u7b2c28\u56de\u5b66\u8853\u5927\u4f1a\uff082015.11, \u7fa4\u99ac\uff09
        \n50.\u7247\u5ca1\u6b63\u660e. \u304c\u3093\u306b\u53b3\u3057\u304f\u60a3\u8005\u3055\u3093\u306b\u3084\u3055\u3057\u3044\u653e\u5c04\u7dda\u6cbb\u7642. \u304c\u3093\u30bb\u30f3\u30bf\u30fc\u30d5\u30a9\u30fc\u30e9\u30e0\uff082015.11, \u677e\u5c71\uff09
        \n51.\u57ce\u6238\u8f1d\u4ec1\uff0e\u653e\u5c04\u7dda\u79d1\u3082\u77e5\u3063\u3066\u304a\u304d\u305f\u3044\u5faa\u74b0\u5668\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u306e\u6d3b\u7528\u6cd5. \u6771\u90e8\u653e\u5c04\u7dda\u7814\u7a76\u4f1a\u3000\u7279\u5225\u8b1b\u6f14\uff082015.11, \u5e83\u5cf6\uff09
        \n52.\u5ddd\u53e3\u76f4\u4eba, \u83ca\u6c60\u9686\u5fb3, \u4e95\u4e0a \u6b66, \u4e09\u6728 \u5747, \u4ed6. N-13\u30a2\u30f3\u30e2\u30cb\u30a2PET\u306b\u3088\u308b\u865a\u8840\u6027\u5fc3\u75be\u60a3\u306e\u8a3a\u65ad\u80fd. \u611b\u5a9bPET\u8b1b\u6f14\u4f1a\uff082015.11, \u677e\u5c71\uff09
        \n53.\u4e95\u4e0a \u6b66. EGFR-TKI failure\u75c7\u4f8b\u306b\u5bfe\u3059\u308b\u8010\u6027\u6a5f\u5e8f\u5225\u500b\u5225\u5316\u6cbb\u7642\u3092\u898b\u636e\u3048\u305fre-biopsy. Scientific Exchange Meeting in\u611b\u5a9b\uff082015.11, \u677e\u5c71\uff09
        \n54.\u4ec1\u4e95\u7530\u308a\u3061. \u53cc\u6975\u6027\u969c\u5bb3\u306e\u9069\u6b63\u306a\u8a3a\u65ad\uff65\u6cbb\u7642\u306e\u305f\u3081\u306b\uff5eMRI\u753b\u50cf\u8a3a\u65ad\u3092\u7528\u3044\u305f\u30a2\u30d7\u30ed\u30fc\u30c1\u301c. \u53cc\u6975\u6027\u969c\u5bb3Webner. (2015.12, \u5168\u56fd\u30a6\u30a7\u30d6\u30bb\u30df\u30ca\u30fc)
        \n55.\u4ec1\u4e95\u7530\u308a\u3061. \u62e1\u6563\u30c6\u30f3\u30bd\u30eb\u753b\u50cf\u3092\u7528\u3044\u305f\u8a8d\u77e5\u75c7\u3068\u3046\u3064\u306e\u9451\u5225. \u4e5d\u5dde\u8133\u795e\u7d4c\u5916\u79d1\u8a8d\u77e5\u75c7\u30a8\u30ad\u30b9\u30d1\u30fc\u30c8\u30df\u30fc\u30c6\u30a3\u30f3\u30b0\uff082015.12, \u718a\u672c\uff09
        \n56.Masao Miyagawa. Invited Lecture at Symposium: CZT based SPECT for myocardial perfusion imaging. \u201cThe impact of a novel SPECT camera with semiconductor detectors on clinical nuclear cardiology.\u201d (2015.12\uff0cAssan Medical Center, Seoul, Korea)
        \n57\u4e95\u4e0a \u6b66. \u7b2c125\u56deJRS\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\u6559\u80b2\u30bb\u30df\u30ca\u30fc\u3000\u753b\u50cf\u8a3a\u65ad\/\u6ccc\u5c3f\u5668. \u7b2c125\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff082015.12, \u9ad8\u77e5\uff09
        \n58.\u5ddd\u53e3\u76f4\u4eba. \u30a2\u30f3\u30e2\u30cb\u30a2PET\u306b\u3064\u3044\u3066. \u7b2c3\u56deEhime Heart IMagE CT\u30cf\u30f3\u30ba\u30aa\u30f3\uff082015.12, \u6771\u6e29\uff09
        \n        <\/a>\u25a0<\/span> \u7814\u7a76\u52a9\u6210<\/strong><\/p>\n
          \n1.\u5009\u7530 \u8056 \u4ed6. \u79d1\u5b66\u7814\u7a76\u8cbb\u52a9\u6210\u4e8b\u696d\uff08\u5b66\u8853\u7814\u7a76\u52a9\u6210\u57fa\u91d1\u52a9\u6210\u91d1\u3001\u57fa\u76e4\u7814\u7a76C\u3001\u5e73\u621027\u5e74\u5ea6\uff09\u3000\u300c\u5fc3\u81d3CT\u306b\u3088\u308b\u51a0\u52d5\u8108\u652f\u914d\u9818\u57df\u306e\u81ea\u52d5\u62bd\u51fa\u3068\u5b9a\u91cf\u8a55\u4fa1\u300d
          \n2.\u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. \u65e5\u672c\u5b66\u8853\u632f\u8208\u4f1a\u3000\u79d1\u7814\u8cbb\u3000\u57fa\u76e4\u7814\u7a76(C) \u7814\u7a76\u8ab2\u984c\u756a\u53f7\uff1a25461829. \u300c\u534a\u5c0e\u4f53SPECT\u3092\u7528\u3044\u305f\u5fc3\u7b4b\u5c40\u6240\u8840\u6d41\u306e\u5b9a\u6027\u30fb\u5b9a\u91cf\u89e3\u6790\u306b\u3088\u308b\u865a\u8840\u6027\u5fc3\u75be\u60a3\u306e\u7dcf\u5408\u8a3a\u65ad\u300d
          \n3.\u671b\u6708\u8f1d\u4e00, \u5bae\u5ddd\u6b63\u7537, \u5927\u6728\u672c\u660e\u7fa9, \u57ce\u6238\u8f1d\u4ec1. \u65e5\u672c\u5b66\u8853\u632f\u8208\u4f1a\u3000\u79d1\u7814\u8cbb\u3000\u57fa\u76e4\u7814\u7a76(C) \u7814\u7a76\u8ab2\u984c\u756a\u53f7\uff1a25461830. \u300c\u5fc3\u30b5\u30eb\u30b3\u30a4\u30c9\u30fc\u30b7\u30b9\u306e\u8a3a\u65ad\u306b\u304a\u3051\u308bFDG-PET\u691c\u67fb\u306e\u6709\u7528\u6027\u306b\u95a2\u3059\u308b\u691c\u8a0e\u300d
          \n4.\u671b\u6708\u8f1d\u4e00, \u5bae\u5ddd\u6b63\u7537. \u611b\u5a9b\u5927\u5b66\u5171\u540c\u7814\u7a76\u3000\u7814\u7a76\u984c\u76ee\u3000\u300c\u534a\u5c0e\u4f53SPECT\u30ab\u30e1\u30e9\u306b\u3088\u308b\u5fc3\u7b4b\u8840\u6d41\u306e\u5b9a\u91cf\u7684\u8a55\u4fa1\u300d \u65e5\u672c\u30e1\u30b8\u30d5\u30a3\u30b8\u30c3\u30af\u30b9(\u682a)
          \n          <\/a>\u25a0<\/span> \u53d7\u8cde<\/strong><\/p>\n
            \n1.\u57ce\u6238\u502b\u4e4b. Yong Investigator Award \u512a\u79c0\u8cde. \u7b2c25\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u753b\u50cf\u52d5\u614b\u5b66\u4f1a\uff082015.1, \u6771\u4eac\uff09
            \n2.\u6d25\u7530\u5b5d\u6cbb. \u611b\u5a9b\u5927\u5b66\u533b\u5b66\u90e8\u4ed8\u5c5e\u75c5\u9662\u6cbb\u9a13\u5b9f\u65bd\u512a\u79c0\u8cde.
            \n3.\u7530\u4ee3\u3089\u307f. \u7b2c15\u56de\u82e5\u624b\u7814\u7a76\u8005\u5968\u52b1\u8cde\u6700\u512a\u79c0\u8cde. \u7b2c25\u56de\u65e5\u672c\u5fc3\u81d3\u6838\u533b\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a (2015.6, \u6771\u4eac)
            \n4.\u798f\u5c71\u76f4\u7d00. \u4e00\u822c\u6f14\u984c\u512a\u79c0\u8cde. \u7b2c\uff19\u56deSCCT\u7814\u7a76\u4f1a\uff082015.9, \u6771\u4eac\uff09
            \n5.\u7530\u908a\u88d5\u8cb4. Young Investigator\u2018s Award\u6700\u512a\u79c0\u8cde. \u7b2c25\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u753b\u50cf\u52d5\u614b\u5b66\u4f1a\uff082015.1, \u6771\u4eac\uff09
            \n6.Tomoyuki Kido. SCMR Regional Scholarship Award. 2015 SCMR\/Euro CMR Joint Scientific Sessions\uff082015.2, Nice, France\uff09
            \n7.Naomi Nakajima. Excellent poster award, 15th International Congress of Radiation Research (2015.5, Kyoto)
            \n8.Tomoyuki Kido. Best young Presenter Award Finalist. The 9th Asian Society of Cardiovascular Imaging (2015.6, Kuala Lumpur, Malaysia)<\/p>\n","protected":false},"excerpt":{"rendered":"

            2015\u5e74\u696d\u7e3e\u3000\u305d\u306e2 \u25a0\u3000\u5b66\u4f1a\u30fb\u7814\u7a76\u4f1a\u767a\u8868 \u56fd\u5185\u5b66\u4f1a\uff08\u5168\u56fd\uff09 \u56fd\u5185\u5b66\u4f1a\uff08\u5730\u65b9\u4f1a\uff09 \u25a0 \u8b1b\u6f14 \u25a0 \u7814\u7a76\u52a9\u6210 \u25a0 \u53d7\u8cde \u8ad6\u6587\u3001\u56fd\u969b\u5b66\u4f1a\u767a\u8868\u306f2015\u5e74\u696d\u7e3e\u3000\u305d\u306e1\u3092\u3054\u89a7\u4e0b\u3055\u3044\u3002 ———& […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[20],"tags":[],"class_list":["post-3374","post","type-post","status-publish","format-standard","hentry","category-20"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/posts\/3374","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/comments?post=3374"}],"version-history":[{"count":0,"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/posts\/3374\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/media?parent=3374"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/categories?post=3374"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/tags?post=3374"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}